Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models

Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates in vitro and in vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models

American College of Rheumatology (ACR) 2025

Veronica Campbell, Yi Zhang, Virginia Massa, Jordan Leedberg, Erik Corcoran, Emily Lurier, Ryan Camire, Christopher Carroll, Chris Ho, Dapeng Chen, Bradley Enerson, Revonda Mehovic, Ziyan Zhao, Lincoln Howarth, Susanne Breitkopf, Sarah Martinez, Melissa Ford, Xue Fei, Murugappan Sathappa, Juliet Williams, Matthew Weiss, Arsalan Shabbir, Nello Mainolfi